How TRT Affects Cholesterol and Lipid Levels

If you're considering TRT and you have any concern about your heart health, your first question is probably: what does this do to my cholesterol?

It's a fair question — and the answer is more nuanced than a simple "good" or "bad." TRT affects the lipid panel, but the changes need to be understood in context of the full metabolic picture.

The Short Answer on Lipids

TRT's effects on cholesterol are modest and generally manageable:

• HDL ("good" cholesterol): Can decrease modestly, typically 5-10 mg/dL, particularly with injectable forms
• LDL ("bad" cholesterol): Variable — some studies show no change, others show modest reductions
• Total cholesterol: Generally slight decrease due to improved metabolic function
• Triglycerides: Often improves (decreases), particularly in men with insulin resistance

The HDL reduction is the finding that most concerns physicians. HDL is classically considered cardioprotective, so a decrease sounds alarming. But here's the critical context: the absolute magnitude of HDL change on TRT is small, and the relationship between HDL levels and cardiovascular outcomes is more complex than the "higher is always better" framework suggests.

Why Treating Low Testosterone Improves the Overall Metabolic Picture

Low testosterone is itself a metabolic disorder. Men with hypogonadism have:

• Increased visceral fat (the metabolically dangerous type)
• Higher insulin resistance
• Higher inflammation markers (IL-6, TNF-alpha, CRP)
• Worse glycemic control

All of these factors are independently associated with cardiovascular disease. When TRT corrects low testosterone and the patient loses visceral fat, improves insulin sensitivity, and reduces systemic inflammation, the net cardiovascular effect is often favorable — even if HDL drops modestly.

This is why looking at the lipid panel in isolation misses the real story. A patient who starts TRT, loses 15 pounds of visceral fat, improves his HbA1c by 0.3 points, and reduces his CRP from 3.2 to 1.1 has improved his cardiovascular risk profile significantly — even if his HDL dropped from 48 to 43 mg/dL.

What the Large Trials Show

The cardiovascular signal from TRT has been studied extensively, culminating in the TRAVERSE trial (2023) — the largest randomized controlled trial of testosterone therapy ever conducted, with over 5,200 men followed for about 3.5 years.

Key TRAVERSE findings: - No significant difference in major adverse cardiovascular events (MACE) between testosterone and placebo groups in men with hypogonadism and established cardiovascular disease or high CV risk - The trial put to rest concerns about TRT causing heart attacks or strokes in appropriately selected patients - There was a higher rate of atrial fibrillation (1.5% vs 0.5%) and pulmonary embolism (0.9% vs 0.5%) in the testosterone group — worth noting, particularly for men with history of AFib or clotting disorders

Prior to TRAVERSE, a concerning 2010 trial was widely cited as evidence that TRT increases cardiovascular events. That trial had significant methodological problems and has been largely discredited. The more rigorous evidence, including the Testosterone Trials and TRAVERSE, points in a safer direction.

Delivery Method Matters

How testosterone is delivered affects lipid changes significantly. This is important for patients deciding between treatment options.

Injectable testosterone (cypionate/enanthate): The delivery method that produces the most variable testosterone levels (peaks and troughs). Associated with modest HDL reduction in some studies. The most common form for cost and convenience reasons.

Topical testosterone (gels/creams): More stable daily levels. Generally associated with smaller lipid changes than injectables.

Testosterone pellets: Long-acting subcutaneous implants. Some data suggests favorable lipid effects compared to injectables, possibly due to more stable levels. Higher cost and procedural requirement.

For patients with lipid concerns or cardiovascular history, discussing delivery method as part of the TRT decision is worth doing with your physician.

The Hematocrit Factor

TRT increases red blood cell production. In most patients this is modest and harmless. In some — particularly those on higher doses or injectable forms — hematocrit can rise significantly (>52-54%), which increases blood viscosity and theoretically cardiovascular risk.

This is why hematocrit is monitored on all Marrow TRT protocols. Elevated hematocrit is managed through dose reduction, switching delivery methods, or occasional blood donation. It's manageable, but it's why monitoring matters.

What to Do if You Have Pre-Existing Lipid Concerns

If you have high LDL or low HDL before starting TRT, the approach should be:

1. Get a comprehensive baseline: Fasting lipid panel, ApoB, Lp(a), and a coronary artery calcium (CAC) score if you're over 40 and have multiple risk factors. These give you a real cardiovascular risk picture, not just surface-level numbers.

1. Address the underlying metabolic issues: If you have high triglycerides and low HDL, you likely have insulin resistance. Treating that — with lifestyle, medication, or GLP-1 therapy — will improve your lipid profile more than any single intervention.

1. Don't let lipid concerns automatically disqualify you from TRT: The net cardiovascular benefit of treating symptomatic hypogonadism often outweighs the small lipid changes from TRT. This is a risk-benefit analysis, not a binary rule.

1. Monitor consistently: Annual lipid panels with your TRT labs are standard practice. Changes get caught early.

The Bottom Line

TRT can modestly reduce HDL cholesterol. In some patients with specific risk factors, this deserves attention. But it's one data point in a much larger cardiovascular risk picture.

The evidence from large trials — including the definitive TRAVERSE trial — shows that appropriately managed TRT in hypogonadal men does not meaningfully increase heart attack or stroke risk. And treating the metabolic dysfunction of low testosterone often improves the overall cardiovascular risk profile more than any isolated lipid change might worsen it.

Monitor your labs, work with a physician who understands the full picture, and don't let a fear of a 5-point HDL change keep you from addressing a real hormonal deficiency.